250 related articles for article (PubMed ID: 33853959)
1. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency.
Mannemuddhu SS; Xu H; Bleck CKE; Tjandra N; Carter C; Bhaduri-McIntosh S
J Virol; 2021 Jun; 95(13):e0246620. PubMed ID: 33853959
[TBL] [Abstract][Full Text] [Related]
2. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
3. Selective Targeting of Virus Replication by Proton Pump Inhibitors.
Watanabe SM; Ehrlich LS; Strickland M; Li X; Soloveva V; Goff AJ; Stauft CB; Bhaduri-McIntosh S; Tjandra N; Carter C
Sci Rep; 2020 Mar; 10(1):4003. PubMed ID: 32132561
[TBL] [Abstract][Full Text] [Related]
4. Role of the TSG101 gene in Epstein-Barr virus late gene transcription.
Chua HH; Lee HH; Chang SS; Lu CC; Yeh TH; Hsu TY; Cheng TH; Cheng JT; Chen MR; Tsai CH
J Virol; 2007 Mar; 81(5):2459-71. PubMed ID: 17182691
[TBL] [Abstract][Full Text] [Related]
5. Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation.
Thomé MP; Borde C; Larsen AK; Henriques JAP; Lenz G; Escargueil AE; Maréchal V
Antiviral Res; 2019 Dec; 172():104615. PubMed ID: 31580916
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function.
Verma D; Thompson J; Swaminathan S
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3609-14. PubMed ID: 26976570
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr Virus Enhances Cancer-Specific Aberrant Splicing of TSG101 Pre-mRNA.
Chua HH; Kameyama T; Mayeda A; Yeh TH
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269659
[TBL] [Abstract][Full Text] [Related]
8. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.
Gorres KL; Daigle D; Mohanram S; McInerney GE; Lyons DE; Miller G
mBio; 2016 Mar; 7(2):e00113. PubMed ID: 26933051
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.
Lee J; Kosowicz JG; Hayward SD; Desai P; Stone J; Lee JM; Liu JO; Ambinder RF
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341058
[TBL] [Abstract][Full Text] [Related]
10. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
[TBL] [Abstract][Full Text] [Related]
11. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
12. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
[TBL] [Abstract][Full Text] [Related]
13. Potent Inhibition of Hepatitis E Virus Release by a Cyclic Peptide Inhibitor of the Interaction between Viral Open Reading Frame 3 Protein and Host Tumor Susceptibility Gene 101.
Anang S; Kaushik N; Hingane S; Kumari A; Gupta J; Asthana S; Shalimar ; Nayak B; Ranjith-Kumar CT; Surjit M
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068652
[TBL] [Abstract][Full Text] [Related]
14. Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation.
Huang L; Yang M; Yuan Y; Li X; Kuang E
Antiviral Res; 2017 Feb; 138():68-78. PubMed ID: 27939840
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase.
Drosu NC; Edelman ER; Housman DE
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12368-12374. PubMed ID: 32409608
[TBL] [Abstract][Full Text] [Related]
16. IFI16 Partners with KAP1 to Maintain Epstein-Barr Virus Latency.
Xu H; Li X; Rousseau BA; Akinyemi IA; Frey TR; Zhou K; Droske LE; Mitchell JA; McIntosh MT; Bhaduri-McIntosh S
J Virol; 2022 Sep; 96(17):e0102822. PubMed ID: 35969079
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin conjugation to Gag is essential for ESCRT-mediated HIV-1 budding.
Sette P; Nagashima K; Piper RC; Bouamr F
Retrovirology; 2013 Jul; 10():79. PubMed ID: 23895345
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
[TBL] [Abstract][Full Text] [Related]
19. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.
Kerr JR
J Clin Pathol; 2019 Oct; 72(10):651-658. PubMed ID: 31315893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
